Picture of Benchmark Holdings logo

BMK — Benchmark Holdings News Story

0.000.00%
gb flag iconLast trade - 00:00
Consumer DefensivesAdventurousSmall CapNeutral

Q3 Results

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240822:nRSV3376Ba&default-theme=true

RNS Number : 3376B  Benchmark Holdings PLC  22 August 2024

22 August 2024

 

Information within this announcement is deemed by the Company to constitute
inside information under the Market Abuse Regulations (EU) No. 596/2014

 

Benchmark Holdings plc

("Benchmark", the "Company" or the "Group")

 

Q3 Results

(Three months and nine months ended 30 June 2024)

 

Solid performance in Genetics and Advanced Nutrition amidst continuing soft
shrimp markets

Completed steps to streamline Health and transition Ectosan® Vet and
CleanTreat® business model

 

In compliance with the terms of the Company's unsecured Green bond, which
requires it to publish quarterly financial information, Benchmark, the
aquaculture biotechnology business, announces its unaudited results for the
three months ended 30 June 2024 (the "Period" or "Q3 FY24"), which constitutes
the third quarter for the fiscal year ("FY") 2024, and its year to date
unaudited results for the nine months ended 30 June 2024 ("Q3 YTD FY24"). All
Q3 FY24, Q3 FY23, Q3 YTD FY24 and Q3 YTD FY23 figures quoted in this
announcement are based on unaudited accounts.

 

Financial highlights

 

Q3 FY24

 

·    Group revenues of £30.7m were 10% below prior year (-7% at constant
exchange rate "CER") driven by:

o  Advanced Nutrition: good trading with 4% increase against the prior year
(+11% CER) despite continuing softness in the shrimp market

o  Genetics: solid trading albeit revenues were 18% (17% CER) below Q3 FY23
reflecting a shift from direct egg sales to indirect sales through Salmar
Genetics, the Group's JV in Norway, as well as a timing difference in harvest
income compared to last year

o  Health: revenues were 43% below last year (-41% CER) reflecting the
decommissioning of the two CleanTreat® units as part of the planned
transition to a new business model for Ectosan® Vet and CleanTreat®

·    15% increase in Adjusted EBITDA excluding fair value ("FV") movement
of biological assets (+19% CER) driven by:

o  Progress across all Genetics growth vectors including Chile, shrimp and
genetic services

o  Higher contribution from the Group's JV in Norway, and

o  Positive impact of streamlined organisation and infrastructure in Health

·    Adjusted EBITDA margin excluding FV movement of biological assets was
15% (Q3 FY23: 12%) resulting from 28% margin in Genetics (Q3 FY23: 16%), 11%
margin in Advanced Nutrition (Q3 FY23: 21%) and breakeven in Health (Q3 FY23:
-27%)

·    Operating Loss was £6.5m (Q3 FY23: £4.0m loss)

·    Ample liquidity and headroom

o  Cash of £17.0m and liquidity of £34.2m (cash and available facility) as
of 30 June 2024

o  Net debt (excluding lease liabilities) £63.9m as at 30 June 2024 (31
March 2024: £56.8m; 30 September 2023: £45.6m)

 

 

Q3 YTD FY24

 

·     Group revenues were £110.9m, 17% below the prior year (-11% CER)
due to:

o Soft conditions in the shrimp markets throughout the year

o Normalised egg volumes in Genetics against last year coupled with shift from
direct egg sales to indirect sales through the Group's JV in Norway

o Lower Health revenues following the decommissioning of the two CleanTreat®
units

·     Adjusted EBITDA excluding FV movement of biological assets was 17%
below the prior year (-10% CER) with an increase in Genetics offset by a
decrease in Advanced Nutrition and Health

·     Adjusted EBITDA margin excluding FV movement from biological assets
was in line with last year at 20% (Q3 YTD FY23: 20%) resulting from 24% margin
in Genetics (Q3 YTD FY23: 18%), 20% margin in Advanced Nutrition (Q3 YTD FY23:
24%) and 17% margin in Health (Q3 YTD FY23: 25%)

·     Operating loss was £10.2m (Q3 YTD FY24: £3.0m)

 

Business Area Highlights

 

·    Advanced Nutrition - good trading in Q3 FY24 against backdrop of
continuing softness in the shrimp market

o  Q3 revenues were 4% ahead of the prior year with good trading partially
offset by forex headwinds (+11% CER)

o  YTD revenues were 1% above the prior year on a constant exchange rate; 7%
below including forex impact

o  Q3 Adjusted EBITDA was lower at £1.8m (Q3 FY23: £3.4m) reflecting lower
margins due to product mix and higher logistics costs as a result of temporary
disruption to trading routes with freight vessels avoiding the regional
insecurity of the Suez Canal by travelling around Cape of Good Hope. Adjusted
EBITDA margin was 11% (Q3 FY23: 21%)

o  YTD Q3 FY24 Adjusted EBITDA margin was 20% (YTD Q3 FY23: 24%)

o  The shrimp market remained soft with green shoots not yet translating into
market recovery.  Despite this the fundamentals remain strong.

§ We maintain commercial focus and take action to optimise our performance
and competitive position including by expanding our product portfolio and
strengthening our presence in key markets

§ Regulators and market participants taking steps to support the aquaculture
sector e.g. reduction of import duty on aquaculture supplies in India and
development of value-added shrimp products in Ecuador to stimulate exports

 

·    Genetics - increase in underlying profitability driven by progress
across all growth vectors - Chile, shrimp and genetic services

o  Q3 revenues 18% below Q3 FY23 (-17% CER) driven by shift against last year
from direct egg sales to indirect sales through the Group's JV in Norway, the
benefit of which is reflected in EBITDA and timing difference in harvest
income compared to last year

o  YTD Q3 revenues -17% (-13% CER) compared to last year which benefitted
from supply constraints in the market in the first part of the year

o  46% increase in Q3 Adjusted EBITDA excluding FV movement of biological
assets driven by:

§ Chile - Adjusted EBITDA excluding FV movement of £0.5m (Q3 FY23: £0.9m
loss)

§ Shrimp - Adjusted EBITDA loss reduced from £0.8m to £0.5m

§ Higher contribution from the JV in Norway

o  Q3 Adjusted EBITDA margin excluding FV movement 28% (Q3 FY23: 16%)

o  YTD Q3 Adjusted EBITDA margin excluding FV movement was 24% (Q3 YTD FY23:
18%)

 

·    Health - significant restructuring and streamlining as part of
transition to new business model for Ectosan® Vet and CleanTreat®

o  Q3 revenues 43% below last year (-41% CER) reflecting the decommissioning
of the CleanTreat® units as part of the planned transition to a new business
model for Ectosan® Vet and CleanTreat®

§ Salmosan® Vet revenue increased 17%

o  Q3 Adjusted EBITDA loss reduced to nil (Q3 FY23 loss: £1.0m) showing the
positive impact of restructuring actions in the seasonally quiet third quarter

o  YTD Q3 Adjusted EBITDA of £2.3m (YTD Q3 FY23: £5.6m); YTD Q3 Adjusted
EBITDA margin of 17% (YTD Q3 FY23: 25%)

o  Business rightsized to deliver Salmosan® Vet solution which will drive
profitability and cash generation post restructuring

o  Maintained capability to deploy Ectosan® Vet and CleanTreat®, a proven
effective solution to address sea lice, subject to customer investment in
CleanTreat® infrastructure

 

Current trading and outlook

 

·    Trading well against backdrop of market headwinds in Advanced
Nutrition and the restructuring in Health which have an impact on short term
performance but support near and long term prospects

o  Good visibility of salmon egg deliveries in Genetics for the remainder of
the year and continued progress in growth vectors

o  Resilience in Advanced Nutrition underpinned by commercial focus and
streamlined efficient organisation

o  Profitable and cash positive Health business following restructuring and
underpinned by good performance of Salmosan® Vet

·    Actions taken during the year bring all business areas to
profitability and set them on the path to deliver shareholder value

Financial Summary (continuing operations)

 £m                                                                               Q3 FY23  % CER     YTD Q3 FY24  YTD Q3 FY23  % CER**

                                                                        Q3 FY24            Q3 FY24                Restated*    Q3 YTD FY24
 Revenue                                                                30.7      34.2     -7%       110.9        132.9        -11%

                                                                        -10%                         -17%
 Adjusted
 Adjusted EBITDA(1)                                                     4.5       5.4      -14%      21.3         28.1         -17%

                                                                        -17%                         -24%
 Adj. EBITDA excluding biological asset fair value movements            4.6       4.0      +19%      21.9         26.4         -10%

                                                                        +15%                         -17%
 Adjusted Operating Profit/(Loss)(2)                                    (0.4)     0.2      -216      5.7          12.6         -43%

                                                                        -278%                        -55%
 Adj. Operating profit excluding biological asset fair value movements  (0.3)     (1.2)    +84%      6.3          10.9         -28%

                                                                        +76%                         -43%
 Statutory
 Operating loss                                                         (6.5)     (4.0)    -57%      (10.2)       (3.0)        -189%

                                                                        -61%                         -238%
 Loss before tax                                                        (9.4)     (4.3)    -118%     (17.3)       (5.4)        -191%

                                                                        -121%                        -217%
 Basic loss per share (p)                                               (1.34)    (0.64)             (2.55)       (1.04)
 Net debt(3)                                                                      (66.9)                          (66.9)
 Net debt(3) excluding lease liabilities                                          (45.7)                          (45.7)

Business Area summary

 £m                                                                        Q3 FY23  % CER     YTD Q3 FY24  YTD Q3 FY23  % CER**

                                                                 Q3 FY24            Q3 FY24                             YTD Q3 FY24
 Revenue
 Advanced Nutrition                                              16.8      16.1     +11%      57.2         61.4         +1%

                                                                 +4%                          -7%
 Genetics                                                        11.8      14.4     -17%      40.2         48.7         -13%

                                                                 -18%                         -17%
 Health                                                          2.2       3.8      -41%      13.6         22.9         -38%

                                                                 -43%                         -40%
 Adjusted EBITDA(1)
 Advanced Nutrition                                              1.8       3.4      -43%      11.7         14.9         -14%

                                                                 -47%                         -22%
 Genetics                                                        3.2       3.7      -13%      9.1          10.3         -6%

                                                                 -14%                         -11%
 -       Net of fair value movements in biological assets        3.3       2.3      +45%      9.7          8.6          +20%

                                                                 +46%                         +13%
 Health                                                          0.0       (1.0)    +104      2.3          5.6          -58%

                                                                 +105%                        -60%

 

*Q3 2023 numbers were restated to reflect certain operations of the Group that
were classified as discontinued operations and divested during that period in
line with IFRS 5 (See Note 5)

** Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates

(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure

(2) Adjusted Operating Profit is operating loss before exceptional items
including acquisition related items and amortisation of intangible assets
excluding development costs

(3) Net debt is cash and cash equivalents less loans and borrowings

 

 

Strategic review

In January 2024, the Company announced that the Board had unanimously decided
to undertake a formal review of the Company's strategic options including a
potential formal sale process. This process remains ongoing and further
updates will be provided as appropriate.

 

Trond Williksen, CEO, commented:

 

"Our two largest business areas, Advanced Nutrition and Genetics, performed
well in Q3. In Genetics, it is particularly pleasing to see continued progress
in our Chilean business as well as the positive results of the recent
reorganisation of our shrimp genetics activities.  Our Advanced Nutrition
business remains resilient to the continuing soft conditions in the shrimp
markets and is well positioned for market recovery.

 

Having streamlined our Health business, rightsizing it to focus on Salmosan®
Vet during the transition period to a new business model for Ectosan® Vet and
CleanTreat®, we now have a profitable business which maintains its capability
to deliver Ectosan® Vet and CleanTreat®."

 

Presentation for analysts and institutional investors at 08.00 UK time (09.00
CEST)

 

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a presentation for analysts and institutional investors on
the day at 08.00 UK time (09.00 CEST).

 

The presentation will be held in person at Haakon Vlls Gate 2, Oslo, Norway.
To register your interest, please contact benchmark@mhpgroup.com
(mailto:benchmark@mhpgroup.com)

 

A live webcast of the presentation will be available for analysts and
investors to join remotely at the following
link: https://channel.royalcast.com/landingpage/hegnarmedia/20240822_11/
(https://protect.checkpoint.com/v2/___https:/channel.royalcast.com/landingpage/hegnarmedia/20240822_11/___.bXQtcHJvZC1jcC1ldXcyLTE6bmV4dDE1OmM6bzplZGE4OTQzOTZmMGU1OTgxNDk1MDkzOWE1YTAzMzdiNTo2OmEwZTM6ZTM5NGExMjdmYzhlMDk3YjU2MGI4ZmE0M2RkOGY4MjFiYWNlMGFhOTJkNDEzOTQ3NGEzOGU4NDY0NTYwMjY0MDpoOkY6Tg)

 

A live webcast of the presentation will be available for analysts and
investors to join remotely at the following link:
link: https://channel.royalcast.com/landingpage/hegnarmedia/20240822_11/
(https://protect.checkpoint.com/v2/___https:/channel.royalcast.com/landingpage/hegnarmedia/20240822_11/___.bXQtcHJvZC1jcC1ldXcyLTE6bmV4dDE1OmM6bzplZGE4OTQzOTZmMGU1OTgxNDk1MDkzOWE1YTAzMzdiNTo2OmEwZTM6ZTM5NGExMjdmYzhlMDk3YjU2MGI4ZmE0M2RkOGY4MjFiYWNlMGFhOTJkNDEzOTQ3NGEzOGU4NDY0NTYwMjY0MDpoOkY6Tg)

 

A copy of the presentation can be found on the Company's website
https://www.benchmarkplc.com/investors/reports-presentations/

 

Equity Development webcast at 12.00 UK time (13:00 CEST)

 

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a second webcast for retail investors and wealth managers on
the day at 12.00 UK time (13:00 CEST). The webcast is open to all existing and
potential shareholders.

 

To register please visit:
https://www.equitydevelopment.co.uk/news-and-events/benchmark-investor-presentation-22aug2024
(https://www.equitydevelopment.co.uk/news-and-events/benchmark-investor-presentation-22aug2024)

 

A recording of the presentation will be available after the event on the
Equity Development website
(https://protect.checkpoint.com/v2/___https:/www.equitydevelopment.co.uk/research/tag/benchmark-holdings___.bXQtcHJvZC1jcC1ldXcyLTE6bmV4dDE1OmM6bzo3ZGQwM2M5ZGE1ODFhNGFkZmQzY2M5ODhkNzJhODJiNzo2OmYxNDk6MTY2MmI4MDMwNmRkMmU4ZTg4Y2VhODdlYjljMDkyMTc0MTVkYjU0MmUzYzI4MGVjOTQ2Y2YwMzRmYzExZDI0ZjpwOlQ6Tg)
.
(https://protect.checkpoint.com/v2/___https:/www.equitydevelopment.co.uk/research/tag/benchmark-holdings___.bXQtcHJvZC1jcC1ldXcyLTE6bmV4dDE1OmM6bzo3ZGQwM2M5ZGE1ODFhNGFkZmQzY2M5ODhkNzJhODJiNzo2OmYxNDk6MTY2MmI4MDMwNmRkMmU4ZTg4Y2VhODdlYjljMDkyMTc0MTVkYjU0MmUzYzI4MGVjOTQ2Y2YwMzRmYzExZDI0ZjpwOlQ6Tg)

 

Enquiries:

 

 For further information, please contact:
 Benchmark Holdings plc                         benchmark@mphc.com
 Trond Williksen, CEO
 Septima Maguire, CFO
 Ivonne Cantu, Investor Relations

 Deutsche Numis (Nominated Adviser and Broker)  Tel:  020 7260 1000
 Freddie Barnfield, Duncan Monteith, Sher Shah

 MHP                                            Tel:   +44 7831 406117

Katie Hunt, Reg
Hoare
 
   benchmark@mhpgroup.com (mailto:benchmark@mhpgroup.com)

 

About Benchmark

Benchmark is a market leading aquaculture biotechnology company. Benchmark's
mission is to drive sustainability in aquaculture by delivering products and
solutions in genetics, advanced nutrition and health which improve yield,
growth and animal health and welfare.

Through a global footprint in 26 countries and a broad portfolio of products
and solutions, Benchmark addresses many of the major aquaculture species -
salmon, shrimp, sea bass and sea bream, and tilapia -   in all the major
aquaculture regions around the world. Find out more at www.benchmarkplc.com

 

 

Management Report

 

Q3 FY24 commentary

 

The Group performed well in Q3 FY24 with solid trading in its two largest
business areas of Advanced Nutrition and Genetics, noting that Q3 is a low
season quarter for the Group in totality.  In Health we continued to
streamline the business, rightsizing our resources to support our Salmosan®
Vet activities during the planned transition to a new business model for
Ectosan® Vet and CleanTreat®. The restructuring of Health was completed post
period end and will result in significant immediate cost savings and a cash
positive business. We have retained the capabilities to deploy Ectosan® Vet
and CleanTreat® onto customer infrastructure be it a barge or integrated
wellboat solution, both of which we are able to support, but now with very low
financial exposure.  Ectosan® Vet and CleanTreat® remains a compelling
solution to the sea lice pressure experienced in the industry.

 

The Group reported revenues of £30.7m in the quarter, 10% below the prior
year (-7% CER). This resulted from revenue growth in Advanced Nutrition of 4%
(+11% CER) offset by 18% lower revenues in Genetics (-17% CER) and a 43% drop
in Health revenues (-41% CER) following the decommissioning of the
CleanTreat® units.  The drop in Genetics revenue is due to a shift from
direct egg sales to indirect sales through the Company's JV in Norway, the
benefit of which is reflected in EBITDA, as well as a difference in the timing
of harvest income against the prior year and lower ancillary revenues.

 

Adjusted EBITDA excluding fair value movement of biological assets was £4.6m,
15% ahead of the prior year (+19% CER) driven by a higher Adjusted EBITDA
excluding fair value uplift in Genetics (+46%) reflecting progress across all
growth vectors - Chile, shrimp and genetic services - and higher JV profits,
together with the positive impact of the restructuring in Health. This was
partially offset by Advanced Nutrition which reported lower Adjusted EBITDA
reflecting a change in product mix and higher costs associated with the
temporary disruption of freight routes due to geopolitical conflicts in the
Suez Canal.

 

Operating costs for the Group of £9.9m were 6% below last year (Q3 FY23:
£10.5m) with a decrease in Genetics, Health and Corporate overheads and a
small increase in Advanced Nutrition. R&D expenses of £1.4m were broadly
in line with the prior year (Q3 FY23: £1.5m).  The Group incurred £2.6m of
exceptional costs in Q3 FY24, including exceptional restructuring costs of
£1.2m relating to the formal review of the Company's strategic options and
other restructuring actions taken.

 

Depreciation and amortisation decreased to £8.4m (Q3 FY23: £8.9m), taking
Group operating loss for the quarter to £6.5m (Q3 FY23: £4.0m).  The
Adjusted Operating loss excluding fair value movements in biological assets
was £0.3m (Q3 FY23: £1.2m loss).

 

Net finance costs were £2.9m, significantly above the comparative period (Q3
FY23: £0.2m) which benefitted from credits from the ineffective portion of
the movement in the fair value of the derivative instrument and forex
movements.  Absent those movements, interest expense including lease interest
was at a similar level to the prior year.  As a result of these year-on-year
movements, the loss before tax in the quarter was £9.4m (Q3 FY23: £4.3m).

 

The tax charge in the period was a £0.5m (Q3 FY23: £0.1m credit).  The
resulting loss after tax for the quarter was £10.0m (Q3 FY23: loss £4.2m).

 

The Group reported a net cash inflow from operating activities of £1.2m (Q3
FY23: £3.9m), Working capital was an outflow of £1.3m (Q3 F2Y23: £1.1m).
Net cash used in investing activities was £0.6m (Q3 FY23: £0.2m inflow) of
which capex was £0.8m (Q3 FY23: £1.1m) offset by proceeds from sale of fixed
assets. During the period, net interest paid was £2.4m and tax paid was
£2.1m. Cash used in financing activities was £2.1m (Q3 FY23: £6.8m). The
Group maintains ample liquidity and headroom with cash of £17m and liquidity
of £34.2m (cash and available liquidity) as of 30 June 2024.

 

Q3 YTD FY24 Commentary

 

Q3 YTD FY24 the Group delivered revenue of £110.9m (Q3 YTD FY23: £132.9m)
with the drop resulting from lower revenues in Genetics against a strong FY23
which benefitted from supply constraints in the market, lower revenues in
Advanced Nutrition as a result of soft shrimp markets and a reduction in
Health following the decommissioning of the CleanTreat® units.

 

Adjusted EBITDA excluding fair value movements from biological assets was
£21.9m (Q3 YTD FY23: £26.4m) with Genetics reporting a 13% increase while
Advanced Nutrition and Health were down 22% and 60% respectively as a result
of lower revenues.

 

Operating costs were £30.2m, a 12% reduction from the prior year (Q3 YTD
FY23: £34.3m). Operating costs were down across all business areas as were
corporate overheads reflecting good cost control, initiatives to improve
efficiency and a resizing of the Health business.  R&D expenses of £4.5m
were in line with the prior year. Total R&D investment including
capitalised development costs was £4.6m (Q3 YTD FY23: £4.9m).

 

The Adjusted EBITDA margin (excluding fair value movement from biological
assets) was 20% (Q3 YTD FY23: 20%).  Depreciation and amortisation decreased
5% from the comparative period last year to £26.5m (Q3 YTD FY23: £27.9m),
leaving the operating loss in the period at £10.2m (Q3 YTD FY22: £3.0m).

 

There was a significant increase in net finance costs for Q3 YTD FY24 to
£7.1m (Q3 YTD FY23: £2.4m), primarily as a result of income from movements
in hedge accounting in the prior year, coupled with increased interest costs
due to higher borrowings during the current year. This is slightly offset by
differences in foreign exchange gains and losses year on year. This led to a
loss before tax of £17.3m (Q3 YTD FY23: £5.4m). The tax charge in the period
of £1.4m was in line with the prior year, leaving loss from continuing
operations at £18.7m (Q3 YTD FY23: £6.9m).

 

Year to date, the Group reported a net operating cash outflow of £2.8m after
a decrease in working capital of £14.1m mainly due to a reduction in trade
payables.  Net cash outflow from investing activities was £2.1m, including
capex of £2.7m including intangibles and capitalised development costs. Our
cash position at the end of the period was £17.0m and liquidity of £34.2m.

 

 

Business Area Commentary

 

Advanced Nutrition

 

Advanced Nutrition revenues were £16.8m, 4% above Q3 FY23 and 11% above last
year on a constant exchange rate basis. This is particularly positive against
a backdrop of continuing softness in the global shrimp market and demonstrates
the success of our commercial focus and the resilience of our business. By
product area, sales of Artemia were +4%, Diets +7% and Health -6% against Q3
FY23.

 

Our gross profit margin in Advanced Nutrition of 48% (Q3 FY23: 59%) reflects a
change in product mix and increased freight costs owing to global geopolitical
conflicts. Operating costs were also slightly above the prior year (+3%) and
as a result Q3 FY24 Adjusted EBITDA was £1.8m (Q3 FY23: £3.4m).

 

YTD Q3 FY24 revenue was £57.2m, 7% behind the prior year (+1% CER) and
Adjusted EBITDA was 22% below (CER -14%) prior year at £11.7m.

 

Strategically we continue to take steps to optimise our operations, to expand
our product portfolio to address specific market opportunities and have plans
to strengthen our presence in certain key markets both directly and through
collaborations.

 

The shrimp market remained soft in the period with green shoots in certain
markets not yet translating into market recovery.  Nevertheless, we remain
confident that we continue to be resilient and well positioned as the market
recovers. At a macro sector level certain countries are taking steps to
support the industry including a reduction in custom duty on aquaculture
supplies in India and a focus on processed high value shrimp products in
Ecuador. These are structural measures which will support the development and
profitability of the industry in the longer term from which we expect to
benefit.

 

Genetics

 

Genetics delivered solid trading in Q3 FY24 despite revenues of £11.8m being
18% below the prior year (-17% CER).  This was driven mainly by lower harvest
income due to the timing of the harvest, and a shift from direct egg sales to
indirect sales through our JV in Norway in the period. Direct sales volume of
salmon eggs was 60m, 8m below Q3 FY23. Total volume of egg sales including
direct sales and indirect sales made through the Group's JV in Norway was 69m,
marginally below the prior year (Q3 FY23: 70m eggs).  YTD Q3 FY24 total
volume of eggs was 258m (YTD Q3 FY23: 275m).

 

Notably all growth vectors performed well in the period. Revenues from Chile
increased 12% taking the Adjusted EBITDA excluding fair value movement from a
loss of £0.9m in Q3 FY23 to a profit of £0.5m. This result also reflects
higher capitalisation of production costs associated with our biological
assets in Chile as we gain commercial traction and there is increased
visibility of future sales. In shrimp our ongoing work to develop local lines
is making good progress and we are starting to benefit from the commercial
integration of our shrimp portfolio led by our Advanced Nutrition business.
While this is not yet evident in material sales volumes, the reorganisation
and integration resulted in significant cost savings reducing the Adjusted
EBITDA loss for our shrimp genetics business from a loss of £0.8m in Q3 FY23
to a loss of £0.5m in the period.

 

Adjusted EBITDA for Q3 FY24 excluding fair value movements of biological
assets was up 46% (+45% CER) to £3.3m (Q3 FY23: £2.3m) due to a higher
contribution from Salmar Genetics, the Group's JV in Norway, improved
performance across all growth vectors and higher capitalisation of production
costs associated with biological assets resulting in a favourable movement
against last year.

 

YTD Q3 FY24 revenues were £40.2m 13% CER below the prior year which
benefitted from supply constraints in the market. Adjusted EBITDA excluding
fair value movement of biological assets was £9.7m (YTD Q3 FY23: £10.6m).
The Adjusted EBITDA margin excluding fair value movement of biological assets
was 24% (YTD Q3 FY23: 19%).

 

Health

 

Revenues in Q3 FY23 were £2.2m, 43% below the prior year (Q3 FY23: £3.8m).
 Sales from Ectosan® Vet and CleanTreat® were £0.9m (Q3 FY23: £2.7m).
 Salmosan® sales were 17% above the prior year at £1.2m.

 

During the quarter we took the second of the two platform supply vessels (PSV)
carrying the CleanTreat® systems out of service and we have streamlined the
rest of the organisation accordingly. As a result, Adjusted EBITDA was nil (Q3
FY23: loss of £1.0m) reflecting cost savings achieved through the
restructuring. We have maintained the capabilities and expertise to deploy
Ectosan® Vet and CleanTreat® subject to customer investment in the
CleanTreat® infrastructure be it a barge or an integrated wellboat.
 Ectosan® Vet and CleanTreat® remains a proven, highly efficacious sea lice
solution capable of addressing the growing sea lice pressure. In addition to
its high efficacy, it offers salmon producers an environmentally friendly way
of treating sea lice with high fish health and welfare credentials.

 

The cost savings associated with the restructuring offset the reduction in
revenues and the business area delivered Adjusted EBITDA of nil (Q3 FY23: 1.0m
loss).

 

YTD revenue was £13.6m (Q3 YTD FY23: £22.9m) reflecting changes in the
business area. YTD Adjusted EBITDA was £2.3m (YTD Q3 FY23 £5.6m).

 

Outlook

 

The Group is trading well against a backdrop of market headwinds in Advanced
Nutrition and the restructuring in Health which have an impact on short term
performance but support near and long term prospects. For the remainder of the
year there is good visibility of salmon egg deliveries in Genetics albeit
below last year when we benefitted from supply constraints in the market, and
expect continued progress in the Genetics growth vectors with the clear aim of
making them increasingly profitable over time.

 

In Advanced Nutrition we expect market conditions to remain soft for the
remainder of the year, but we are confident that we have a resilient,
efficient organisation capable of operating well in this environment and which
is well positioned to benefit from future market recovery.

 

In Health, following the streamlining implemented this year we expect to have
a profitable and cash positive business underpinned by good performance of
Salmosan® Vet.

 

Overall, the actions and progress achieved this year will bring all business
areas to profitability and on a path to deliver shareholder value in the near
and long term.

 

 All figures in £000's                                                Notes  Q3 2024       Q3 2023       YTD Q3 2024   YTD Q3 2023   FY 2023

(unaudited)
Restated*
(unaudited)
Restated*
(audited)

(unaudited)
(unaudited)
 Revenue                                                              4      30,689        34,224        110,913       132,883       169,476
 Cost of sales                                                               (15,071)      (16,715)      (56,047)      (66,052)      (82,726)
 Gross profit                                                                15,618        17,509        54,866        66,831        86,750
 Research and development costs                                              (1,409)       (1,493)       (4,468)       (4,478)       (6,069)
 Other operating costs                                                       (9,879)       (10,521)      (30,231)      (34,292)      (45,157)
 Share of profit/(loss) of equity-accounted investees, net of tax            185           (55)          1,170         1             (32)
 Adjusted EBITDA²                                                            4,515         5,440         21,337        28,062        35,492
 Exceptional - restructuring, acquisition and disposal related items  6      (2,586)       (530)         (5,065)       (3,218)       (3,904)
 EBITDA¹                                                                     1,929         4,910         16,272        24,844        31,588
 Depreciation and impairment                                                 (4,284)       (4,626)       (13,851)      (13,640)      (18,409)
 Amortisation and impairment                                                 (4,140)       (4,318)       (12,629)      (14,230)      (18,495)
 Operating loss                                                              (6,495)       (4,034)       (10,208)      (3,026)       (5,316)
 Finance cost                                                         7      (3,536)       (2,972)       (8,977)       (13,180)      (15,048)
 Finance income                                                       7      612           2,746         1,905         10,762        7,670
 Loss before taxation                                                        (9,419)       (4,260)       (17,280)      (5,444)       (12,694)
 Tax on loss                                                          8      (529)         76            (1,439)       (1,407)       (3,365)
 Loss from continuing operations                                             (9,948)       (4,184)       (18,719)      (6,851)       (16,059)
 Discontinued operations
 Loss from discontinued operations, net of tax                        5      -             (438)         -             (1,170)       (5,505)
                                                                             (9,948)       (4,622)       (18,719)      (8,021)       (21,564)
 Loss for the year attributable to:
 - Owners of the parent                                                      (9,913)       (4,760)       (18,861)      (8,763)       (23,146)
 - Non-controlling interest                                                  (35)          138           142           742           1,582
                                                                             (9,948)       (4,622)       (18,719)      (8,021)       (21,564)

 Earnings per share
 Basic loss per share (pence)                                         9      (1.34)        (0.64)        (2.55)        (1.20)        (3.16)
 Diluted loss per share (pence)                                       9      (1.34)        (0.64)        (2.55)        (1.20)        (3.16)
 Earnings per share - continuing operations
 Basic loss per share (pence)                                         9      (1.34)        (0.58)        (2.55)        (1.04)        (2.41)
 Diluted loss per share (pence)                                       9      (1.34)        (0.58)        (2.55)        (1.04)        (2.41)

 Adjusted EBITDA from continuing operations                                  4,515         5,440         21,337        28,062        35,492
 Adjusted EBITDA from discontinued operations                         5      -             (353)         -             (915)         (1,254)
 Total Adjusted EBITDA                                                       4,515         5,087         21,337        27,147        34,238

 

 

1 EBITDA - Earnings before interest, tax, depreciation, amortisation, and
impairment

2 Adjusted EBITDA - EBITDA before exceptional items including acquisition
related items

* Q3 2023 numbers were restated to reflect certain operations of the Group
that were classified as discontinued operations during FY23 in line with IFRS
5. (See Note 5).

 

The accompanying notes are an integral part of this consolidated financial
information.

 

 All figures in £000's                                                        Q3 2024       Q3 2023       YTD Q3 2024       YTD Q3 2023       FY 2023

(unaudited)
Restated
(unaudited)
Restated
(audited)

(unaudited)
(unaudited)

 Loss for the period                                                          (9,948)       (4,622)       (18,719)          (8,021)           (21,564)
 Other comprehensive income
 Items that are or may be reclassified subsequently to profit or loss
 Foreign exchange translation differences                                     (497)         (11,153)      (11,489)          (35,166)          (23,475)
 Cash flow hedges - changes in fair value                                     701           2,093         (1,644)           1,794             (2,123)
 Cash flow hedges - reclassified to profit or loss                            (475)         (273)         1,139             (565)             2,623
 Total comprehensive income for the period                                    (10,219)      (13,955)      (30,713)          (41,958)          (44,539)

 Total comprehensive income for the period attributable to:
 - Owners of the parent                                                       (10,270)      (14,204)      (30,607)          (42,250)          (45,404)
 - Non-controlling interest                                                   51            249           (106)             292               865
                                                                              (10,219)      (13,955)      (30,713)          (41,958)          (44,539)

 Total comprehensive income for the period attributable to owners of the
 parent:
 - Continuing operations                                                      (10,270)      (13,705)      (30,607)          (40,753)          (39,777)
 - Discontinued operations*                                                   -             (499)         -                 (1,497)           (5,627)
                                                                              (10,270)      (14,204)      (30,607)          (42,250)          (45,404)

 

 

*Total comprehensive income for the period relating to discontinued operations
for Q3 2024 includes the loss of £nil (Q3 2023: £438,000) and foreign
exchange loss of £nil (Q3 2023: £61,000). FY23 includes the loss of
£5,505,000 and foreign exchange loss of £122,000.

 

The accompanying notes are an integral part of this consolidated financial
information.

 

                                                                          30 June 2024  30 June 2023  30 September 2023
 All figures in £000's                                             Notes  (unaudited)   (unaudited)   (audited)
 Assets
 Property, plant and equipment                                            66,505        71,880        73,411
 Right-of-use assets                                                      12,284        21,755        19,804
 Intangible assets                                                        186,841       205,312       206,077
 Equity-accounted investees                                               4,833         3,028         3,558
 Other investments                                                        1             13            14
 Biological and agricultural assets                                       2,748         21,688        18,406
 Non-current assets                                                       273,212       323,676       321,270
 Inventories                                                              24,096        26,244        25,269
 Biological and agricultural assets                                       42,507        21,301        27,586
 Trade and other receivables                                              50,590        47,858        59,795
 Cash and cash equivalents                                                16,984        32,858        36,525
                                                                          134,177       128,261       149,175
 Assets held for sale                                              10     -             850           850
 Current assets                                                           134,177       129,111       150,025
 Total assets                                                             407,389       452,787       471,295
 Liabilities
 Trade and other payables                                                 (27,847)      (32,034)      (47,329)
 Loans and borrowings                                              11     (15,571)      (21,757)      (20,045)
 Corporation tax liability                                                (4,101)       (6,791)       (6,422)
 Provisions                                                               (2,007)       (1,557)       (1,280)
 Current liabilities                                                      (49,526)      (62,139)      (75,076)
 Loans and borrowings                                              11     (76,482)      (77,960)      (81,954)
 Other payables                                                           (7,713)       (4,908)       (6,842)
 Deferred tax                                                             (20,242)      (22,755)      (24,106)
 Provisions                                                               -             -             (700)
 Non-current liabilities                                                  (104,437)     (105,623)     (113,602)
 Total liabilities                                                        (153,963)     (167,762)     (188,678)
 Net assets                                                               253,426       285,025       282,617
 Issued capital and reserves attributable to owners of the parent
 Share capital                                                     12     740           739           739
 Additional paid-in share capital                                  12     37,490        37,428        37,428
 Capital redemption reserve                                               5             5             5
 Retained earnings                                                        166,087       197,168       183,489
 Hedging reserve                                                          (708)         526           (203)
 Foreign exchange reserve                                                 43,706        43,520        54,947
 Equity attributable to owners of the parent                              247,320       279,386       276,405
 Non-controlling interest                                                 6,106         5,639         6,212
 Total equity and reserves                                                253,426       285,025       282,617

 

 

The accompanying notes are an integral part of this consolidated financial
information.

 

                                                      Share     Additional paid-in share capital    Other       Hedging      Retained     Total attributable       Non-          Total

capital
reserves*
reserve
 earnings
 to equity holders of
controlling
equity

parent
interest
                                                      £000      £000                                £000        £000         £000         £000                     £000          £000

 As at 1 October 2023 (audited)                      739       37,428                              54,952      (203)        183,489      276,405                  6,212         282,617
 Comprehensive income/(loss) for the period
 Profit/(loss) for the period                        -         -                                   -           -            (18,861)     (18,861)                 142           (18,719)
 Other comprehensive loss                            -         -                                   (11,241)    (505)        -            (11,746)                 (248)         (11,994)
 Total comprehensive income/(loss) for the period    -         -                                   (11,241)    (505)        (18,861)     (30,607)                 (106)         (30,713)
 Contributions by and distributions to owners
 Share issue                                         1         62                                  -           -            -            63                       -             63
 Share-based payment                                 -         -                                   -           -            1,459        1,459                    -             1,459
 Total contributions by and distributions to owners  1         62                                  -           -            1,459        1,522                    -             1,522
 Total transactions with owners of the Company       1         62                                  -           -            1,459        1,522                    -             1,522
 As at 30 June 2024 (unaudited)                      740       37,490                              43,711      (708)        166,087      247,320                  6,106         253,426

 As at 1 October 2022 (audited)                      704       420,824                             77,710      (703)        (185,136)    313,399                  9,886         323,285
 Comprehensive income/(loss)for the period
 Profit/(loss) for the period                        -         -                                   -           -            (9,294)      (9,294)                  1,273         (8,021)
 Other comprehensive income/(loss)                   -         -                                   (34,185)    1,229        -            (32,956)                 (981)         (33,937)
 Total comprehensive income/(loss)for the period     -         -                                   (35,185)    1,229        (9,294)      (42,250)                 292           (41,958)
 Contributions by and distributions to owners
 Share issue                                         35        12,985                              -           -            -            13,020                   -             13,020
 Share issue costs recognised through equity         -         (2,146)                             -           -            -            (2,146)                  -             (2,146)
 Cancellation of part of share premium account       -         (394,235)                           -           -            394,235      -                        -             -
 Share-based payment                                 -         -                                   -           -            833          833                      -             833
 Total contributions by and distributions to owners  35        (383,396)                           -           -            395,068      11,707                   -             11,707
 Changes in ownership
 Acquisition of NCI                                                                                -                        (3,470)      (3,470)                  (4,539)       (8,009)
 Total changes in ownership interests                -         -                                   -           -            (3,470)      (3,470)                  (4,539)       (8,009)
 Total transactions with owners of the Company       35        (383,396)                           -           -            391,598      8,237                    (4,539)       3,698
 As at 30 June 2023 (unaudited)                      739       37,428                              43,525      526          197,168      279,386                  5,639         285,025

 As at 1 October 2022 (audited)                      704       420,824                             77,710      (703)        (185,136)    313,399                  9,886         323,285
 Comprehensive income/(loss) for the period
 Profit/(loss) for the period                        -         -                                   -           -            (23,146)     (23,146)                 1,582         (21,564)
 Other comprehensive income/loss)                    -         -                                   (22,758)    500          -            (22,258)                 (717)         (22,975)
 Total comprehensive income/(loss) for the period    -         -                                   (22,758)    500          (23,146)     (45,404)                 865           (44,539)
 Contributions by and distributions to owners
 Share issue                                         35        12,985                              -           -            -            13,020                   -             13,020
 Share issue costs recognised through equity         -         (2,146)                             -           -            -            (2,146)                  -             (2,146)
 Cancellation of part of share premium account       -         (394,235)                           -           -            394,235      -                        -             -
 Share-based payment                                 -         -                                   -           -            1,006        1,006                    -             1,006
 Total contributions by and distributions to owners  35        (383,396)                           -           -            395,241      11,880                   -             11,880
 Changes in ownership
 Acquisition of NCI                                  -         -                                   -           -            (3,470)      (3,470)                  (4,539)       (8,009)
 Total changes in ownership interests                -         -                                   -           -            (3,470)      (3,470)                  (4,539)       (8,009)
 Total transactions with owners of the Company       35        (383,396)                           -           -            391,771      8,410                    (4,539)       3,871
 As at 30 September 2023 (audited)                   739       37,428                              54,952      (203)        183,489      276,405                  6,212         282,617

 

*Other reserves in this statement is an aggregation of capital redemption
reserve and foreign exchange reserve

 

The accompanying notes are an integral part of this consolidated financial
information.

 

 All figures in £000's                                                          Q3 2024       Q3 2023       YTD Q3 2024   YTD Q3 2023   FY 2023

(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
 Cash flows from operating activities
 Loss for the period                                                            (9,948)       (4,622)       (18,719)      (8,021)       (21,564)
 Adjustments for:
 Depreciation and impairment of property, plant and equipment                   2,854         2,115         7,921         6,363         8,453
 Depreciation and impairment of right-of-use assets                             1,430         2,587         5,930         7,505         10,260
 Amortisation and impairment of intangible fixed assets                         4,140         4,318         12,629        14,230        18,495
 Profit on sale of property, plant and equipment                                (106)         -             (332)         (36)          (121)
 Loss on sale of discontinued operation                                         -             -             -             -             3,774
 Finance income                                                                 (65)          (1,226)       (351)         (4,195)       (2,802)
 Finance costs                                                                  2,916         2,806         8,311         7,173         10,535
 Loss on disposal of investments in joint ventures                              -             -             (42)          -             -
 Share of (profit)/loss of equity-accounted investees, net of tax               (186)         54            (1,171)       (1)           32
 Foreign exchange (gains)/losses                                                345           (1,336)       10            (2,443)       (1,814)
 Share-based payment expense                                                    654           358           1,458         833           1,005
 Tax charge/(credit)                                                            530           (75)          1,440         1,407         3,365
 Decrease/(increase) in trade and other receivables                             3,762         (2,299)       6,104         3,772         (6,570)
 Decrease/(increase) in inventories                                             (1,510)       (268)         237           2,249         2,877
 Increase in biological and agricultural assets                                 (1,322)       (1,296)       (1,204)       (403)         (1,659)
 (Decrease)/Increase in trade and other payables                                (2,415)       2,811         (18,372)      (10,862)      3,909
 Decrease /(increase) in provisions                                             164           (7)           (839)         (20)          386
                                                                                1,243         3,920         3,010         17,551        28,561
 Income taxes paid                                                              (2,101)       (2,194)       (5,818)       (6,335)       (8,556)
 Net cash flows generated from operating activities                             (858)         1,726         (2,808)       11,216        20,005
 Investing activities
 Acquisition of subsidiaries                                                    -             (48)          -             (48)          (48)
 Purchase of investments in associates                                          (81)          (52)          (224)         (359)         (558)
 Receipts from disposal of subsidiaries, joint ventures, and other investments  -             1,250         37            1,250         1,250
 Purchases of property, plant and equipment                                     (628)         (917)         (2,398)       (4,171)       (5,953)
 Purchase of intangibles                                                        (70)          (43)          (155)         (120)         (196)
 Capitalised research and development costs                                     (56)          (183)         (150)         (380)         (632)
 Proceeds from sale of fixed assets                                             134           22            405           99            227
 Cash receipts from swap contracts                                              -             -             -             -             11
 Interest received                                                              65            150           351           469           627
 Net cash flows used in investing activities                                    (636)         179           (2,134)       (3,260)       (5,272)
 Financing activities
 Proceeds of share issues                                                       -             -             -             13,000        13,000
 Proceeds from exercise of share options                                        62            -             62            20            20
 Share-issue costs recognised through equity                                    -             (496)         -             (2,146)       (2,146)
 Acquisition of minority interests in subsidiaries                              -             -             -             (8,009)       (8,009)
 Proceeds from bank or other borrowings, net of borrowing fees                  2,454         23            2,195         20,825        21,847
 Repayment of bank or other borrowings                                          (371)         (967)         (1,617)       (17,527)      (18,470)
 Interest and finance charges paid                                              (2,418)       (2,654)       (6,925)       (6,736)       (9,131)
 Repayments of lease liabilities                                                (1,817)       (2,660)       (7,185)       (7,349)       (9,438)
 Net cash used in financing activities                                          (2,090)       (6,754)       (13,470)      (7,922)       (12,327)
 Net increase/(decrease) in cash and cash equivalents                           (3,584)       (4,849)       (18,412)      34            2,406
 Cash and cash equivalents at beginning of period                               20,759        38,647        36,525        36,399        36,399
 Effect of movements in exchange rate                                           (191)         (940)         (1,129)       (3,575)       (2,280)
 Cash and cash equivalents at end of period                                     16,984        32,858        16,984        32,858        36,525

 The accompanying notes are an integral part of this consolidated financial
information.

 

1.       Basis of preparation

 

Benchmark Holdings plc (the 'Company') is a company incorporated and domiciled
in the United Kingdom. These consolidated quarterly financial statements as at
and for the nine months ended 30 June 2024 comprises those of the Company and
its subsidiaries (together referred to as the 'Group').

 

These consolidated quarterly financial statements do not comprise statutory
accounts within the meaning of section 434 of the Companies Act 2006 and are
unaudited. These financial statements do not include all the information
required for a complete set of IFRS financial statements. However, selected
explanatory notes are included to explain events and transactions that are
significant to an understanding of the changes in the Group's financial
position and performance since the last annual financial statements. The
Group's last annual statutory financial statements as at and for the year
ended 30 September 2023 were prepared in accordance with (i) UK-adopted
International Accounting Standards and (ii) IFRS adopted pursuant to
Regulation (EC) No. 1606/2002 as it applied in the European Union ("Adopted
IFRS") and are available from the Company's website at www.benchmarkplc.com
(http://www.benchmarkplc.com) .

 

The prior year comparatives are derived from audited financial information for
Benchmark Holdings PLC Group as set out in the Annual Report and Accounts for
the year ended 30 September 2023 and the unaudited financial information in
the Quarterly Financial Report for the nine months ended 30 June 2023. The
comparative figures for the financial year ended 30 September 2023 are not the
Company's statutory accounts for that financial year. Those accounts were
approved by the Directors on 29 November 2023 and have been delivered to the
Registrar of Companies. The audit report received on those accounts was (i)
unqualified and (ii) did not contain a statement under section 498(2) or (3)
of the Companies Act 2006.

 

Statement of Compliance

 

These consolidated quarterly financial statements have been prepared and
approved by the Directors in accordance with UK and EU adopted IAS 34 'Interim
Financial Reporting'. These financial statements do not include all of the
information required for the full annual financial statements and should be
read in conjunction with the Group's last annual consolidated financial
statements as at and for the year ended 30 September 2023. These consolidated
quarterly financial statements were approved by the Board of Directors on 22
August 2024.

 

Going concern

 

The Group's business activities, together with the factors likely to affect
its future development, performance and position are set out in the Management
Report.

 

As at 30 June 2024 the Group had net assets of £253.4m (30 September 2023:
£282.6m), including cash of £17.0m (30 September 2023: £36.5m) as set out
in the consolidated balance sheet. The Group made a total loss for the period
of £18.7m (year ended 30 September 2023: loss £21.6m).

 

The Directors have reviewed forecasts and cash flow projections for a period
of at least 12 months including downside sensitivity assumptions in relation
to trading performance across the Group to assess the impact on the Group's
trading and cash flow forecasts and on the forecast compliance with the
covenants included within the Group's financing arrangements.

 

In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts. Key
downside sensitivities modelled included assumptions on slower
commercialisation of SPR shrimp, slower salmon egg sales growth in Chile and
removal of an additional financing opportunity within Genetics, along with
sensitivity of lower sales growth from a possible slower recovery in the
shrimp market in Advanced Nutrition. The post balance sheet restructuring of
the Health business area to focus on the Salmosan business has derisked the
cash utilisation improving the likelihood of cash generation within that
business area for the foreseeable future. Mitigating measures within the
control of management have been identified should they be required in response
to these sensitivities, including reductions in areas of discretionary spend,
tight control over new hires, deferral of capital projects and temporary hold
on R&D for non-imminent products.

 

On 26 March 2024 an additional facility of £7.5m was added to the existing
RCF with an expiry date of 31 March 2025. The original £20m RCF term remains
unaltered, ending on 27 June 2025.

 

The Board believes that the current share price materially undervalues the
combined value of Benchmark's businesses and the long-term prospects of the
Company.  Consequently, the Board announced on 22 January 2024 the decision
to undertake a formal review of the Company's strategic options, which include
a potential sale of the Company as a whole or of one or more of the individual
business units. The sales process is ongoing, but there are currently no deals
identified or underway and all parts of the business are operating as usual,
so there is no impact on the Directors' assessment of going concern.

 

Dependent on the outcome of the strategic review the board do not see any
issues with refinancing the debt, given the strong relationships with banks
and the previous success with past refinancing. Based on their assessment of
all of the above, the directors believe it remains appropriate to prepare the
financial statements on a going concern basis. However, while the Directors
remain confident that the current facilities will be renewed or replaced over
the next 12 months, the requirement to do this represents a material
uncertainty that may cast significant doubt on the Group's ability to continue
as a going concern and therefore to continue realising its assets and
discharging its liabilities in the normal course of business. The financial
statements do not include any adjustments that would result from the going
concern assumption being inappropriate

 

2.      Accounting policies

 

The accounting policies adopted are consistent with those used in preparing
the consolidated financial statements for the financial year ended 30
September 2023.

 

Taxes on income in the interim periods are accrued using the tax rate that
would be applicable to expected total earnings.

Alternative performance measures ('APMs')

The Directors measure the performance of the Group based on a range of
financial measures, including measures not recognised by UK or EU-adopted
IFRS. These APMs may not be directly comparable with other companies' APMs,
and the Directors do not intend these as a substitute for, or superior to,
IFRS measures.

Directors have presented the performance measures Adjusted EBITDA, Adjusted
Operating Profit, Adjusted Profit Before Tax and Adjusted EBITDA excluding
fair value movement on biological assets because they monitor performance at a
consolidated level using these and believe that these measures are relevant to
an understanding of the Group's financial performance (see note 13).
Furthermore, the Directors also refer to current period results using constant
currency, which are derived by retranslating current period results using the
prior year's foreign exchange rates.

Use of estimates and judgements

The preparation of quarterly financial information requires management to make
certain judgements, estimates and assumptions that affect the application of
accounting policies and the reported amounts of assets and liabilities, income
and expense. Actual amounts may differ from these estimates.

 

In preparing these quarterly financial statements the significant judgements
made by management in applying the Group's accounting policies and the key
sources of estimation uncertainty were the same as those applied to the
consolidated financial statements for the year ended 30 September 2023.

 

3.      Segment information

 

Operating segments are reported in a manner consistent with the reports made
to the chief operating decision maker. It is considered that the role of chief
operating decision maker is performed by the Board of Directors.

 

The Group operates globally and for management purposes is organised into
reportable segments based on the following business areas:

 

·      Genetics - harnesses industry leading salmon breeding
technologies combined with state-of-the-art production facilities to provide a
range of year-round high genetic merit ova.

·      Advanced Nutrition - manufactures and provides technically
advanced nutrition and health products to the global aquaculture industry.

·      Health - the segment provides health products and services to the
global aquaculture market.

 

In order to reconcile the segmental analysis to the consolidated income
statement, corporate and inter-segment sales are also shown. Corporate sales
represent revenues earned from recharging certain central costs to the
operating business areas, together with unallocated central costs.

Measurement of operating segment profit or loss

Inter-segment sales are priced along the same lines as sales to external
customers, with an appropriate discount being applied to encourage use of
Group resources at a rate acceptable to local tax authorities.  This policy
was applied consistently throughout the current and prior period.

 

3.     Segment information (continued)

 

Reconciliations of segmental information to IFRS measures

 

  Segmental Revenue
  All figures in £000's    Q3 2024       Q3 2023        YTD Q3 2024   YTD Q3 2023    FY 2023

(unaudited)
(unaudited)*
(unaudited)
(unaudited)*
(audited)*
   Genetics                11,778        14,426         40,173        48,907         65,791
   Advanced Nutrition      16,784        16,067         57,197        61,391         78,503
   Health                  2,168         3,795          13,628        22,872         25,514
   Corporate               1,054         1,426          3,752         4,299          5,747
   Inter-segment sales     (1,095)       (1,447)        (3,837)       (4,340)        (5,811)
   Total                   30,689        34,267         110,913       133,129        169,744

 

  Segmental Adjusted EBITDA
  All figures in £000's        Q3 2024       Q3 2023       YTD Q3 2024    YTD Q3 2023    FY 2023

(unaudited)
(unaudited)*
(unaudited)
(unaudited)*
(audited)*
   Genetics                   3,204         3,356          9,127         9,339          14,409
   Advanced Nutrition         1,795         3,420          11,671        14,886         18,374
   Health                     48            (1,022)        2,254         5,628          4,772
   Corporate                  (532)         (667)          (1,715)       (2,706)        (3,317)
   Total                      4,515         5,087          21,337        27,147         34,238

 

  Reconciliation of Reportable Segments Adjusted EBITDA to Loss before
 taxation
  All figures in £000's                                                  Q3 2024       Q3 2023       YTD Q3 2024    YTD Q3 2023    FY 2023

(unaudited)
(unaudited)*
(unaudited)
(unaudited)*
(audited)*
  Total reportable segment Adjusted EBITDA                              5,047         5,754          23,052        29,853         37,555
  Corporate Adjusted EBITDA                                             (532)         (667)          (1,715)       (2,706)        (3,317)
  Adjusted EBITDA                                                       4,515         5,087          21,337        27,147         34,238
  Exceptional - restructuring, acquisition and disposal related items   (2,586)       (530)          (5,065)       (3,218)        (7,817)
  Depreciation and impairment                                           (4,284)       (4,702)        (13,851)      (13,868)       (18,713)
  Amortisation and impairment                                           (4,140)       (4,318)        (12,629)      (14,230)       (18,495)
  Net finance costs                                                     (2,924)       (235)          (7,072)       (2,445)        (7,412)
  Loss before taxation                                                  (9,419)       (4,698)        (17,280)      (6,614)        (18,199)

 

  Reconciliation of segmental information to IFRS measures - Revenue and Loss
 before tax
  Revenue
                                                          Q3 2024        Q3 2023       YTD Q3 2024     YTD Q3 2023    FY 2023

(unaudited)
(unaudited)*
(unaudited)
(unaudited)*
(audited)
  Total revenue per segmental information                30,689         34,267         110,913        133,129        169,744
  Less: revenue from discontinued operations             -              (43)           -              (246)          (268)
  Consolidated revenue                                   30,689         34,224         110,913        132,883        169,476

  Loss before tax
                                                          Q3 2024        Q3 2023       YTD Q3 2024     YTD Q3 2023    FY 2023

(unaudited)
(unaudited)*
(unaudited)
(unaudited)*
(audited)
  Profit/(loss) before tax per segmental information     (9,419)        (4,698)        (17,280)       (6,614)        (18,199)
  Less: loss before tax from discontinued operations     -              438            -              1,170          5,505
  Consolidated Profit/(loss) before tax                  (9,419)        (4,260)        (17,280)       (5,444)        (12,694)

* Results include discontinued operations, see note 5 for further detail

4.     Revenue

 

The Group's operations and main revenue streams are those described in its
financial statements to 30 September 2023. The Group's revenue is derived from
contracts with customers.

 

Disaggregation of revenue

 

In the following tables, revenue is disaggregated by primary geographical
market and by sales of goods and services. The table includes a reconciliation
of the disaggregated revenue with the Group's reportable segments (see note
3).

 

Sale of goods and provision of services

 

                          3 months ended 30 June 2024 (unaudited)
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total     Discontinued    Continuing
  Sale of goods           11,292      16,749                1,723      -            -                      29,764    -               29,764
  Provision of services   480         -                     445        -            -                      925       -               925
  Inter-segment sales     6           35                    -          1,054        (1,095)                -         -               -
                          11,778      16,784                2,168      1,054        (1,095)                30,689    -               30,689

                          3 months ended 30 June 2023 (unaudited)
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total     Discontinued    Continuing
  Sale of goods           13,523      16,049                2,259      -            -                      31,831    43              31,788
  Provision of services   900         -                     1,536      -            -                      2,436     -               2,436
  Inter-segment sales     3           18                    -          1,426        (1,447)                -         -               -
                          14,426      16,067                3,795      1,426        (1,447)                34,267    43              34,224

                          9 months ended 30 June 2024 (unaudited)
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total     Discontinued    Continuing
  Sale of goods           38,820      57,090                10,805     -            -                      106,715   -               106,715
  Provision of services   1,341       34                    2,823      -            -                      4,198     -               4,198
  Inter-segment sales     12          73                    -          3,752        (3,837)                -         -               -
                          40,173      57,197                13,628     3,752        (3,837)                110,913   -               110,913

                          9 months ended 30 June 2023 (unaudited)
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total     Discontinued    Continuing
  Sale of goods           45,727      61,356                15,823     -            -                      122,906   246             122,660
  Provision of services   3,174       -                     7,049      -            -                      10,223    -               10,223
  Inter-segment sales     6           35                    -          4,299        (4,340)                -         -               -
                          48,907      61,391                22,872     4,299        (4,340)                133,129   246             132,883

                          12 months ended 30 September 2023 (audited)
 All figures in £000's     Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total     Discontinued    Continuing
  Sale of goods           61,372      78,449                17,707     -            -                      157,528   268             157,260
  Provision of services   4,409       -                     7,807      -            -                      12,216    -               12,216
  Inter-segment sales     10          54                    -          5,747        (5,811)                -         -               -
                          65,791      78,503                25,514     5,747        (5,811)                169,744   268             169,476

4.     Revenue (continued)

 

Primary geographical markets

 

                         3 months ended 30 June 2024 (unaudited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total    Discontinued    Continuing
   Norway                5,992       436                   999        -            -                      7,427    -               7,427
  Vietnam                12          2,040                 -          -            -                      2,052    -               2,052
  Iceland                1,962       -                     57         -            -                      2,019    -               2,019
  Greece                 -           1,792                 -          -            -                      1,792    -               1,792
   Faroe Islands         1,301       -                     417        -            -                      1,718    -               1,718
  Venezuela              -           1,633                 -          -            -                      1,633    -               1,633
  Ecuador                -           1,395                 -          -            -                      1,395    -               1,395
  India                  -           1,331                 -          -            -                      1,331    -               1,331
  Indonesia              110         1,153                 -          -            -                      1,263    -               1,263
  Turkey                 -           1,086                 -          -            -                      1,086    -               1,086
  Chile                  364         -                     327        -            -                      691      -               691
  Rest of Europe         948         651                   157        -            -                      1,756    -               1,756
  Rest of World          1,083       5,232                 211        -            -                      6,526    -               6,526
  Inter-segment sales    6           35                    -          1,054        (1,095)                -        -               -
                         11,778      16,784                2,168      1,054        (1,095)                30,689   -               30,689

                         3 months ended 30 June 2023 (unaudited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total    Discontinued    Continuing
   Norway                7,190       349                   3,155      -            -                      10,694   -               10,694
  Vietnam                -           2,445                 -          -            -                      2,445    -               2,445
  Iceland                1,166       -                     -          -            -                      1,166    -               1,166
  Greece                 -           1,698                 -          -            -                      1,698    -               1,698
   Faroe Islands         1,668       -                     116        -            -                      1,784    -               1,784
  Venezuela              -           680                   -          -            -                      680      -               680
  Ecuador                9           1,936                 -          -            -                      1,945    -               1,945
  India                  -           671                   -          -            -                      671      -               671
  Indonesia              98          705                   -          -            -                      803      -               803
  Turkey                 54          1,208                 -          -            -                      1,262    -               1,262
  Chile                  332         1                     291        -            -                      624      -               624
  Rest of Europe         1,166       794                   93         -            -                      2,053    -               2,053
  Rest of World          2,740       5,562                 140        -            -                      8,442    43              8,399
  Inter-segment sales    3           18                    -          1,426        (1,447)                -        -               -
                         14,426      16,067                3,795      1,426        (1,447)                34,267   43              34,224

 

 

4.     Revenue (continued)

 

Primary geographical markets (continued)

 

                         9 months ended 30 June 2024 (unaudited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total    Discontinued    Continuing
   Norway                22,422      885                   8,158      -            -                      31,465   -               31,465
  Vietnam                12          6,746                 -          -            -                      6,758    -               6,758
  Iceland                4,673       -                     57         -            -                      4,730    -               4,730
  Greece                 -           5,451                 -          -            -                      5,451    -               5,451
   Faroe Islands         4,011       -                     919        -            -                      4,930    -               4,930
  Venezuela              157         2,567                 -          -            -                      2,724    -               2,724
  Ecuador                40          4,617                 -          -            -                      4,657    -               4,657
  India                  -           8,065                 -          -            -                      8,065    -               8,065
  Indonesia              268         3,289                 -          -            -                      3,557    -               3,557
  Turkey                 9           5,300                 -          -            -                      5,309    -               5,309
  Chile                  3,357       -                     1,369      -            -                      4,726    -               4,726
  Rest of Europe         2,998       4,094                 302        -            -                      7,394    -               7,394
  Rest of World          2,214       16,110                2,823      -            -                      21,147   -               21,147
  Inter-segment sales    12          73                    -          3,752        (3,837)                -        -               -
                         40,173      57,197                13,628     3,752        (3,837)                110,913  -               110,913

                         9 months ended 30 June 2023 (unaudited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total    Discontinued    Continuing
   Norway                30,251      691                   17,607     -            -                      48,549   -               48,549
  Vietnam                -           7,470                 -          -            -                      7,470    -               7,470
  Iceland                4,138       -                     -          -            -                      4,138    -               4,138
  Greece                 -           5,969                 -          -            -                      5,969    -               5,969
   Faroe Islands         4,988       -                     464        -            -                      5,452    -               5,452
  Venezuela              43          1,584                 -          -            -                      1,627    -               1,627
  Ecuador                38          5,508                 -          -            -                      5,546    -               5,546
  India                  -           7,696                 -          -            -                      7,696    -               7,696
  Indonesia              436         2,815                 -          -            -                      3,251    -               3,251
  Turkey                 56          5,940                 -          -            -                      5,996    -               5,996
  Chile                  1,465       12                    633        -            -                      2,110    -               2,110
  Rest of Europe         3,486       4,162                 136        -            -                      7,784    -               7,784
  Rest of World          4,000       19,509                4,032      -            -                      27,541   246             27,295
  Inter-segment sales    6           35                    -          4,299        (4,340)                -        -               -
                         48,907      61,391                22,872     4,299        (4,340)                133,129  246             132,883

 

 

4.     Revenue (continued)

 

Primary geographical markets (continued

                         12 months ended 30 September 2023 (audited)
 All figures in £000's    Genetics    Advanced Nutrition     Health    Corporate    Inter-segment sales    Total     Discontinued    Continuing
   Norway                39,007      897                   19,596     -            -                      59,500    -               59,500
  Vietnam                -           11,229                -          -            -                      11,229    -               11,229
  Iceland                7,343       -                     -          -            -                      7,343     -               7,343
  Greece                 -           6,759                 -          -            -                      6,759     -               6,759
   Faroe Islands         6,160       -                     718        -            -                      6,878     -               6,878
  Venezuela              43          2,019                 -          -            -                      2,062     -               2,062
  Ecuador                38          7,257                 -          -            -                      7,295     -               7,295
  India                  -           9,743                 -          -            -                      9,743     -               9,743
  Indonesia              637         4,099                 -          -            -                      4,736     -               4,736
  Turkey                 93          7,009                 -          -            -                      7,102     -               7,102
  Chile                  1,824       12                    991        -            -                      2,827     -               2,827
  Rest of Europe         5,427       4,941                 177        -            -                      10,545    -               10,545
  Rest of World          5,209       24,484                4,032      -            -                      33,725    268             33,457
  Inter-segment sales    10          54                    -          5,747        (5,811)                -         -               -
                         65,791      78,503                25,514     5,747        (5,811)                169,744   268             169,476

 

 

5.     Discontinued activities

During FY23, the group divested its tilapia business for consideration of USD
1 in a management buy out. Consequently, these operations were classified as
discontinued in the prior year and a restatement of the consolidated income
statement.

 

Summary of restatement of Q3 FY23 results as reported in Q3 FY24 financial
statements

                                            Continuing operations         Discontinued operations
 All figures in £000's                      Revenue      Adjusted EBITDA  Loss from continuing operations  Loss from discontinued operations
 As stated in Q3 FY23 financial statements  133,129      27,147           (8,021)                          -
 Reclassified in Q1                         (73)         368              453                              (453)
 Reclassified in Q2                         (130)        194              279                              (279)
 Reclassified in Q3                         (43)         353              438                              (438)
 As stated in Q3 FY24 financial statements  132,883      28,062           (6,851)                          (1,170)

 

Results from discontinued operations

                                                            Q3 FY24  Q3 FY23  YTD Q3 FY24  YTD Q3 FY23  FY23
                                                            £000     £000     £000         £000         £000
 Revenue                                                    -        43       -            246          268
 Cost of sales                                              -        (275)    -            (755)        (973)
 Gross profit                                               -        (232)    -            (509)        (705)
 Research and development costs                             -        (3)      -            (16)         (59)
 Other operating costs                                      -        (118)    -            (390)        (490)
 Share of profit of equity-accounted investees, net of tax  -        -        -            -            -
 Adjusted EBITDA                                            -        (353)    -            (915)        (1,254)
 Exceptional loss on disposal                               -        -        -            -            (3,913)
 EBITDA                                                     -        (353)    -            (915)        (5,167)
 Depreciation and impairment                                -        (76)     -            (228)        (304)
 Amortisation and impairment                                -        -        -            -            -
 Operating loss / Loss before taxation                      -        (429)    -            (1,143)      (5,471)
 Net finance costs                                          -        (9)      -            (27)         (34)
 Loss before taxation                                       -        (438)    -            (1,170)      (5,505)
 Tax on loss                                                -        -        -            -            -
 Loss from discontinued operations                          -        (438)    -            (1,170)      (5,505)

 

 

Exceptional items within discontinued operations

 

                                            Q3 FY24  Q3 FY23  YTD Q3 FY24  YTD Q3 FY23  FY23
                                            £000     £000     £000         £000         £000

 Profit/(loss) on disposal of subsidiaries  -        -        -            -            3,774
 Profit/(loss) on other asset disposals     -        -        -            -            139
 Total exceptional recognised               -        -        -            -            3,913

 

Results from discontinued operations by segment

The results from discontinued operations relate solely to the Genetics
operating segment.

 

6.     Exceptional items from continuing operations -
restructuring/acquisition and disposal related items

 

Items that are material because of their size or nature, are non-recurring and
whose significance is sufficient to warrant separate disclosure and
identification within the consolidated financial statements are referred to as
exceptional items. The separate reporting of exceptional items helps to
provide an understanding of the Group's underlying performance.

 

 All figures in £000's                Q3 2024       Q3 2023       YTD Q3 2024   YTD Q3 2023   FY 2023

(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)
  Acquisition related items           -             579           -             579           652
  Exceptional restructuring costs     1,957         152           4,612         2,825         3,470
  Disposal related items              629           (201)         452           (186)         (218)
 Total exceptional items              2,586         530           5,065         3,218         3,904

 

In Q3 2023, YTD Q3 2023 and FY 2023 acquisition related items comprise fees
incurred in the year in connection with an aborted acquisition.

 

Exceptional restructuring costs include £1.2m in the quarter (Q3 2023 £nil)
and £3.0m YTD (YTD 2023: £nil) relating to the formal review of the
Company's strategic options and the potential sale. Other restructuring costs
include £0.8m for the quarter (Q3 2023: £0.1m) and £1.6m YTD (YTD 2023
£0.2m, FY 2023 £0.9m). In addition to this in FY 23 there were £2.6m (Q3
2023: £0.1m, YTD 2023: £2.6m) of legal and professional costs in relation to
preparing for listing the Group on the Oslo stock exchange.

 

Disposal related items in the quarter relate to uninsured culling of
broodstock and clean-up costs of £0.6m. Additionally, there was a gain of
£0.2m in the YTD for the sale of equipment in relation to a business disposed
of in prior years. In FY 2023 there was a credit of £0.2m for additional
contingent consideration received and receivable relating to the disposal of a
business from 2020, which was slightly offset by other disposal related costs.

 

7.     Net finance costs from continuing operations

 All figures in £000's                                                 Q3 2024       Q3 2023       YTD Q3 2024   YTD Q3 2023   FY 2023

(unaudited)
Restated
(unaudited)
Restated
(audited)

(unaudited)
(unaudited)
 Interest received on bank deposits                                    65            155           351           472           627
 Foreign exchange gains on financing activities                        -             158           -             158           158
 Foreign exchange gains on operating activities                        547           1,363         1,554         6,409         4,709
 Cash flow hedges - reclassified from OCI                              -             273           -             565           -
 Cash flow hedges - ineffective portion of changes in fair value       -             798           -             3,158         2,176
 Finance income                                                        612           2,746         1,905         10,762        7,670
 Leases (interest portion)                                             (385)         (381)         (1,075)       (1,235)       (1,620)
 Foreign exchange losses on operating activities                       (620)         (175)         (666)         (6,034)       (4,547)
 Interest expense on financial liabilities measured at amortised cost  (2,531)       (2,416)       (7,236)       (5,911)       (8,881)
 Finance costs                                                         (3,536)       (2,972)       (8,977)       (13,180)      (15,048)
 Net finance costs recognised in profit or loss                        (2,924)       (226)         (7,072)       (2,418)       (7,378)

 

 

8.     Taxation

 

 All figures in £000's                                     Q3 2024       Q3 2023       YTD Q3 2024   YTD Q3 2023   FY 2023

(unaudited)
(unaudited)
(unaudited)
(unaudited)
(audited)

 Analysis of charge in period
 Current tax:
 Current income tax expense on profits for the period      1,617         823           4,243         3,658         6,178
 Adjustment in respect of prior periods                    -             -             -             -             (880)
 Total current tax charge                                  1,617         823           4,243         3,658         5,298

 Deferred tax:
 Origination and reversal of temporary differences         (1,088)       (899)         (2,804)       (2,251)       (1,933)
 Total deferred tax charge/(credit)                        (1,088)       (899)         (2,804)       (2,251)       (1,933)
                                                                                                     -             -
 Total tax charge                                          529           (76)          1,439         1,407         3,365

 

9.     Loss per share

 

Basic loss per share is calculated by dividing the loss attributable to
ordinary equity holders of the Company by the weighted average number of
ordinary shares in issue during the period.

                                                         Q3 2024               Q3 2023               YTD Q3 2024   YTD Q3 2023   FY 2023

(unaudited)
Restated
(unaudited)
Restated
(audited)

(unaudited)
(unaudited)
 Loss attributable to equity holders of the parent (£000)
 Continuing operations                                   (9,913)               (4,322)               (18,861)      (7,593)       (17,641)
 Discontinued operations                                 -                     (438)                 -             (1,170)       (5,505)
 Total                                                   (9,913)               (4,760)               (18,861)      (8,763)       (23,146)

 Weighted average number of shares in issue (thousands)  739,708               739,300               739,507       729,437       731,935

 Basic loss per share (pence)
 Continuing operations                                   (1.34)                (0.58)                (2.55)        (1.04)        (2.41)
 Discontinued operations                                 -                     (0.06)                -             (0.16)        (0.75)
 Total                                                   (1.34)                (0.64)                (2.55)        (1.20)        (3.16)

 

Diluted loss per share is calculated by adjusting the weighted average number
of ordinary shares outstanding to assume conversion of all dilutive potential
ordinary shares. This is done by calculating the number of shares that could
have been acquired at fair value (determined as the average market price of
the Company's shares for the period) based on the monetary value of the
subscription rights attached to outstanding share options and warrants. The
number of shares calculated above is compared with the number of shares that
would have been issued assuming the exercise of the share options and
warrants.

 

Therefore, the Company is required to adjust the earnings per share
calculation in relation to the share options that are in issue under the
Company's share-based incentive schemes, and outstanding warrants. However, as
any potential ordinary shares would be anti-dilutive due to losses being made
there is no difference between Basic loss per share and Diluted loss per share
for any of the periods being reported.

 

A total of 13,716,299 potential ordinary shares have not been included within
the calculation of statutory diluted loss per share for the year (30 September
2023: 8,948,132 and 30 June 2023: 5,988,043). These potential ordinary shares
could dilute earnings/loss per share in the future.

10.   Assets held for sale

 

During 2022, management committed to sell certain property, plant and
equipment held within the Health business area. The property concerned was
longer required by the business and the decision was made to sell. The market
value of the property fell during the period and a further impairment charge
of £200,000 was incurred to write the asset down to its current market value
of £300,000 (30 September 2023: £850,000). The property was sold for
£300,000 on 28 March 2024.

 

There were no liabilities directly associated with the assets held for sale.

 

 Assets held for sale               YTD Q3 2024   YTD Q3 2023   FY 2023

(unaudited)
(unaudited)
(audited)
 All figures in £000's
 Property, plant and equipment      -             850           850
 Total Assets held for sale         -             850           850

 

11. Loans and borrowings

 

                               YTD Q2 2024   YTD Q3 2023   FY 2023

(unaudited)
(unaudited)
(audited)
 All figures in £000's
 Non-Current
 2025 750m NOK Loan notes      55,706        53,382        57,604
 Bank borrowings               14,642        15,746        16,799
 Unamortised debt issue costs  (111)         -             (742)
 Lease liabilities             6,245         8,832         8,293
                               76,482        77,960        81,954
 Current
 Bank borrowings               11,779        9,439         9,320
 Unamortised debt issue costs  (1,093)       -             (842)
 Lease liabilities             4,885         12,318        11,567
                               15,571        21,757        20,045
 Total loans and borrowings    92,053        99,717        101,999

 

The Group has an unsecured floating rate listed green bond of NOK 750m in
issue. The bond which matures in September 2025, has a coupon of three-month
NIBOR + 6.50% p.a. with quarterly interest payments, and is listed on the Oslo
Stock Exchange.

 

The Group has a secured GBP 20m RCF provided by DNB Bank ASA, maturing on 27
June 2025. This facility was extended on the same terms in March 2024 by GBP
7.5m, to a total facility of GBP 27.5m, with the GBP 7.5m extension maturing
on 27 March 2025. The margin on this combined facility is a minimum of 2.75%
and a maximum of 3.25%, dependent upon the leverage of the Group above the
relevant risk-free reference or IBOR rates depending on which currency is
drawn. As at 30 June 2024 there was £17.25m undrawn.

 

Additionally, Benchmark Genetics Salten AS had the following loans (which are
ring-fenced debt without recourse to the remainder of the Group) at 30 June
2024:

 

•      term loan with Nordea Bank with a balance of NOK 160.5m, which
has a maturity date of five years ending 15 January 2028 and an interest rate
of 2.5% above three-month NIBOR.

•      twelve month working capital facility of NOK 20.0m provided by
Nordea Bank Norge Abp. This was undrawn at 30 June 2024

•      term loan with a balance of NOK 32.1m provided by Innovasjon
Norge. The loan is a 12-and-a-half year term loan maturing in March 2031. The
interest rate on this loan at 30 June 2024 was 6.7%

•      an additional 15-year term loan with a balance of NOK 9.5m
provided by Innovasjon Norge and maturing in July 2038. The interest rate on
this loan at 30 June 2024 was 6.7%

•      a loan of NOK 15.5m provided by the minority shareholder Salten
Stamfisk AS. The loan attracts interest at 2.5% above three-month NIBOR and is
repayable on maturity of the Nordea loan above.

12.   Share capital and additional paid-in share capital

                                     Number       Share Capital  Additional paid-in

share capital
 Allotted, called up and fully paid               £000           £000
 Ordinary shares of 0.1 pence each
 Balance at 30 September 2023        739,352,390  739            37,428
 Exercise of share options           426,253      1              62
 Balance at 31 March 2024            739,778,643  740            37,490

 

13.   Alternative performance measures and other metrics

 

Management has presented the performance measures EBITDA, Adjusted EBITDA,
Adjusted EBITDA before fair value movement in biological assets, Adjusted
Operating Profit and Adjusted Profit Before Tax because it monitors
performance at a consolidated level using these and believes that these
measures are relevant to an understanding of the Group's financial
performance.

 

Adjusted EBITDA which reflects underlying profitability, is earnings before
interest, tax, depreciation, amortisation, impairment, and exceptional items
and is shown on the Income Statement.

 

Adjusted EBITDA before fair value movements in biological assets, which is
Adjusted EBITDA before the non-cash fair value movements in biological assets
arising from their revaluation in line with International Accounting
Standards.

 

Adjusted Operating Profit is operating loss before exceptional items and
amortisation and impairment of intangible assets excluding development costs
as reconciled below.

 

Adjusted Profit Before Tax is earnings before tax, amortisation and impairment
of intangibles assets excluding development costs, and exceptional items as
reconciled below. These measures are not defined performance measures in IFRS.
The Group's definition of these measures may not be comparable with similarly
titled performance measures and disclosures by other entities.

 

Reconciliation of Adjusted Operating Profit/(loss) to Operating Profit/(loss)

 All figures in £000's                                                             Q3 2024       Q3 2023       YTD Q3 2024   YTD Q3 2023   FY 2023

(unaudited)
Restated
(unaudited)
Restated
(audited)

(unaudited)
(unaudited)
 Revenue                                                                           30,689        34,224        110,913       132,883       169,476
 Cost of sales                                                                     (15,071)      (16,715)      (56,047)      (66,052)      (82,726)
 Gross profit                                                                      15,618        17,509        54,866        66,831        86,750
 Research and development costs                                                    (1,409)       (1,493)       (4,468)       (4,478)       (6,069)
 Other operating costs                                                             (9,879)       (10,521)      (30,231)      (34,292)      (45,157)
 Depreciation and impairment                                                       (4,284)       (4,626)       (13,851)      (13,640)      (18,409)
 Amortisation of capitalised development costs                                     (604)         (606)         (1,815)       (1,833)       (2,437)
 Share of profit/(loss) of equity accounted investees net of tax                   185           (55)          1,170         1             (32)
 Adjusted operating (loss)/profit                                                  (373)         208           5,671         12,589        14,646
 Exceptional - restructuring, acquisition and disposal related items               (2,586)       (530)         (5,065)       (3,218)       (3,904)
 Amortisation and impairment of intangible assets excluding development costs      (3,536)       (3,712)       (10,814)      (12,397)      (16,058)
 Operating loss                                                                    (6,495)       (4,034)       (10,208)      (3,026)       (5,316)

 

 

13.    Alternative performance measures and other metrics (continued)

 

Reconciliation of Loss Before Taxation to Adjusted Profit Before Tax

 All figures in £000's                                                             Q3 2024       Q3 2023       YTD Q3 2024   YTD Q3 2023   FY 2023

(unaudited)
Restated
(unaudited)
Restated
(audited)

(unaudited)
(unaudited)

 Loss before taxation                                                              (9,419)       (4,260)       (17,280)      (5,444)       (12,694)
 Exceptional - restructuring, acquisition and disposal related items               2,586         530           5,065         3,218         3,904
 Amortisation and impairment of intangible assets excluding development costs      3,536         3,712         10,814        12,397        16,058
 Adjusted (loss)profit before tax                                                  (3,297)       (18)          (1,401)       10,171        7,268

 

Other Metrics

 All figures in £000's                                                   Q3 2024       Q3 2023       YTD Q3 2024   YTD Q3 2023    FY 2023

(unaudited)
Restated
(unaudited)
Restated
(audited)

(unaudited)
(unaudited)
 Total R&D Investment
 Research and development costs
 - Continuing operations                                                 1,409         1,493         4,468         4,478          6,069
 - Discontinued operations                                               -             3             -             16             59
 Internal capitalised development costs                                  56            183           150           380            632
 Total R&D investment                                                    1,465         1,679         4,618         4,874          6,760
 All figures in £000's                                                    Q3 2024       Q3 2023      YTD Q3 2024    YTD Q3 2023    FY 2023

(unaudited)
Restated
(unaudited)
Restated
(audited)

(unaudited)
(unaudited)
 Adjusted EBITDA excluding fair value movement in biological assets
 Adjusted EBITDA                                                         4,515         5,440         21,337        28,062         35,492
 Exclude fair value movement                                             73            (1,457)       580           (1,704)        103
 Adjusted EBITDA excluding fair value movement in biological assets      4,588         3,983         21,917        26,358         35,595

 

Liquidity

 

A key financial covenant is a minimum liquidity of £10m, defined as cash plus
undrawn facilities.

 

 All figures in £000's         30 June 2024 (unaudited)    30 June 2023 (unaudited)    FY 2023

(audited)
 Cash and cash equivalents    16,984                      32,858                      36,525
 Undrawn bank facility        17,250                      12,250                      12,250
 Total liquidity              34,234                      45,108                      48,775

 

The undrawn bank facility relates to the RCF facility.  At 30 June 2024,
£10.25m of the RCF was drawn (30 June 2023: £7.75m, 30 September 2023:
£7.75m), leaving £17.25m undrawn (30 June 2023: £12.25m, 30 September 2023:
£12.25m).

 

 

14.   Net debt

Net debt is cash and cash equivalents less loans and borrowings.

                                                                     30 June 2024  30 June 2023  30 September 2023
 All figures in £000's                                               (unaudited)   (unaudited)   (audited)
 Cash and cash equivalents                                           16,984        32,858        36,525
 Loans and borrowings (excluding lease liabilities) - current        (10,686)      (9,439)       (8,478)
 Loans and borrowings (excluding lease liabilities) - non-current    (70,237)      (69,128)      (73,661)
 Net debt excluding lease liabilities                                (63,939)      (45,709)      (45,614)
 Lease liabilities - current                                         (4,885)       (12,318)      (11,567)
 Lease liabilities - non-current                                     (6,245)       (8,832)       (8,293)
 Net debt                                                            (75,069)      (66,859)      (65,474)

 

15.   Post Balance sheet event

After the period end in July 2024, the decision was made to restructure the
Health business area.  The restructuring exercise will reduce operating
expenditure in the business area by streamlining resource to focus on the
Salmosan and Purisan business whilst discussions with customers about
investing in the new operating models continue.  The technical capability to
roll out the CleanTreat® infrastructure onto customer owned platforms upon
getting customer commitment is being retained.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  QRTPPUCWRUPCPUG

Recent news on Benchmark Holdings

See all news